medicalxpress - Pfizer was poised to seal a takeover of Metsera on Saturday after its improved offer won over the biotechnology startup's board and Danish challenger Novo Nordisk called a halt to a back-and-forth bidding war.
AI Summary: In a dramatic bidding war for a promising biotech startup, Pfizer’s improved $10 billion offer prevailed—until Novo Nordisk raised its bid yet again. This high-stakes takeover tussle underscores the fierce competition and strategic importance of emerging therapies.
Pfizer Triumphs in $10B Metsera Bidding War / 6 months
Neurocrine buys Soleno Therapeutics for $2.9B to gain Prader‑Willi drug / 7 wks
Novo Nordisk commits $2.1B to Vivtex to pursue oral obesity medicines / 2 months
Novo Nordisk GLP‑1 Trials Fail to Check Alzheimer’s Progression / 6 months
Novo Nordisk Seeks FDA Nod for Higher‐Dose Wegovy / 6 months
Biogen announces $5.6B acquisition of Apellis Pharma / 1 month
Gilead buys Ouro Medicines for about $1.68–1.7B to bolster autoimmune pipeline / 2 months
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.